Enhabit (EHAB) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US29332G1022
Enhabit, Inc., traded as EHAB on the NYSE, is a leading provider of home health and hospice services in the United States.
Its comprehensive home health services encompass patient education, pain management, wound care, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services. Enhabit also specializes in treating chronic diseases such as diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and chronic pain. Additionally, the company's disease-specific plans cater to patients with diabetes, congestive heart failure, post-orthopedic surgery, injury, and respiratory diseases. Enhabit's team of physical, occupational, and speech therapists offer top-notch therapy services.
Enhabit extends its services to hospice care, offering pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services. Their hospice services are designed to address the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families.
Operating across 23 states, Enhabit, Inc. has a robust presence with 252 home health agencies and 105 hospice agencies as of December 31, 2022. Formerly known as Encompass Health Home Health Holdings, Inc., the company rebranded to Enhabit, Inc. in March 2022. Established in 2014, Enhabit, Inc. is headquartered in Dallas, Texas. For more information, visit their website at https://www.ehab.com.
Drawdown (Underwater) Chart
EHAB Stock Overview
Market Cap in USD | 501m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC SubIndustry | Health Care Services |
TER | 0.00% |
IPO / Inception | 2022-07-01 |
EHAB Stock Ratings
Growth 5y | -4.70 |
Fundamental | -39.0 |
Dividend | - |
Rel. Performance vs Sector | -3.91 |
Analysts | 3.00/5 |
Fair Price Momentum | 8.11 USD |
Fair Price DCF | 8.98 USD |
EHAB Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
EHAB Growth Ratios
Growth 12m | -21.33% |
Growth Correlation 12m | -38% |
Growth Correlation 3m | 20% |
CAGR 5y | -39.56% |
Sharpe Ratio 12m | -0.44 |
Alpha vs SP500 12m | -38.31 |
Beta vs SP500 5y weekly | 0.54 |
ValueRay RSI | 25.28 |
Volatility GJR Garch 1y | 52.34% |
Price / SMA 50 | -6.19% |
Price / SMA 200 | -7.62% |
Current Volume | 370k |
Average Volume 20d | 319.2k |
External Links for EHAB Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 09, 2024, the stock is trading at USD 9.70 with a total of 370,003 shares traded.
Over the past week, the price has changed by -4.72%, over one month by -12.38%, over three months by +8.99% and over the past year by -28.09%.
According to ValueRays Forecast Model, EHAB Enhabit will be worth about 8.8 in May 2025. The stock is currently trading at 9.70. This means that the stock has a potential downside of -9.79%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 10.9 | 12.7 |
Analysts Target Price | 11.1 | 14.2 |
ValueRay Target Price | 8.8 | -9.79 |